A New Development in Cancer Immunotherapy: DNA-Encoded Anti-CTLA4 Monoclonal Antibodies

Immune checkpoint inhibitors are a new generation of immunotherapies that have brought revolutionary advances in cancer treatment. Their use as standard treatment in many cancers has greatly transformed oncology, a development effectively recognized by the 2018 Nobel Prize .
Note: Molecules such as CTLA4, PD-1 and PD-L1 are among the immune system's checkpoints; immune cells recognize other cells as friend or foe through molecules like these.
Anti-CTLA4 and anti-PD-L1 monoclonal antibody immunotherapy drugs have received approval for clinical use. Recently, studies on using genetic technologies in monoclonal antibody treatments had increased. In October 2018, Cancer Research published a study describing the design of DNA -encoded anti-CTLA4 monoclonal antibodies. In other words, synthetic DNA technology allows anti-CTLA4 antibodies to be produced inside the body.
Monoclonal antibodiesprovide effective treatment against cancer but present challenges, such as a very complex manufacturing process and the need for repeated dosing. A new method using genetic techniques has been developed to overcome these problems. In the research, synthetic DNA plasmids encoding anti-CTLA4 monoclonal antibodies were designed. When this plasmid is injected into muscle tissue, cells produce anti-CTLA4 from the DNA-containing plasmid. The aim is thus to achieve a long-lasting effect with a single dose . In other words, instead of expensive immunotherapies administered every 14 or 21 days, a single plasmid administration in vaccine form.
Note: A plasmidis a piece of DNA separate from the chromosome that can replicate itself. It is typically circular and double-stranded. It is generally found in bacteria and sometimes in eukaryotes (human cells).
Studies in mouse models observed complete regression in tumor models after treatment. Fighter T cells were also successfully activated. Mouse models successfully showed that DNA-encoded anti-CTLA4 monoclonal antibodies had the same anticancer effect and reached the same serum concentration as conventional anti-CTLA4 monoclonal antibodies.
What Does This Study Tell Us?
- For the first time, DNA-encoded monoclonal antibodies targeting CTLA4 were designed. These antibodies target the CTLA4 molecule that allows cancer cells to evade the immune system .
- This is the first study showing that synthetic DNA technology can be used in cancer immunotherapy.
- Rather than receiving a monoclonal antibody directly, the aim is to produce antibodies inside the body through plasmids. This may improve the success of cancer treatments.
- It must be emphasized that these plasmids are still being tested at the preclinical stage. They will be available for use after safety has been proven in human clinical studies.
In the figure below, cancer immunotherapy—immune checkpoint inhibitors—the subject of the 2018 Nobel Prize in Medicine, can be seen.

Sources
Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces tumor shrinkage in vivo.
Cancer Research, 4 October 2018.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.